Company / Shareholders' Equity
Black Diamond Therapeutics, Inc. Shareholders' Equity History
FY2019-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$307.8M
FY2020
5-year range
-$47.2M / $307.8M
FY2019-FY2020
Trend
+752.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$308M in FY2020.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, shareholders' equity increased 752.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $307.8M | +752.6% |
| FY2019 | -$47.2M | - |
As of FY2020 · SEC Form 10-K · Last checked Jun 21, 2026